Trial Profile
A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipatasertib (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Advanced breast cancer; Triple negative breast cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms LOTUS
- Sponsors Genentech; Roche
- 01 Sep 2021 Results of final overall survival results of the double-blind placebo-controlled randomized phase 2 LOTUS trial, published in the Breast Cancer Research and Treatment
- 15 Nov 2019 Status changed from active, no longer recruiting to completed.
- 11 Oct 2019 This trial has been completed in France, according to European Clinical Trials Database record.